<DOC>
	<DOCNO>NCT01114542</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial evaluate effect blood glucose-lowering effect NN1250 ( insulin degludec ) subject type 1 diabetes .</brief_summary>
	<brief_title>A Trial Evaluating Effect NN1250 Steady State Conditions Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) least 12 month Current total daily insulin treatment low 1.2 ( I ) U/kg/day Body mass index 18.028.0 kg/m^2 Subject donate blood plasma past month 500 mL within 3 month prior screen Smoker ( define subject smoke 5 cigarette equivalent per day ) Not able willing refrain smoking use nicotine gum transdermal nicotine patch inpatient period Supine blood pressure screening ( rest 5 min ) outside range 90140 mmHg systolic 5090 mmHg diastolic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>